Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. (7th January 2021)

• Record Type: Journal Article
• Authors: Morrisette, Taylor; Alosaimy, Sara; Philley, Julie V; Wadle, Carly; Howard, Catessa; Webb, Andrew J; Veve, Michael P; Barger, Melissa L; Bouchard, Jeannette; Gore, Tristan W; Lagnf, Abdalhamid M; Ansari, Iman; Mejia-Chew, Carlos; Cohen, Keira A; Rybak, Michael J
• Is Part Of: Open forum infectious diseases. Volume 8:Number 2(2021)
• Publication Date: 2021-01-07
• Subjects: Mycobacterium abscessus -- omadacycline -- rapidly growing nontuberculous mycobacteria; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab002
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus . The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.